Monopar Therapeutics Inc
Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. The company develops ALXN1840, a late-stage, investigational once-daily and oral medicine; MNPR-101, a proprietary humanized monoclonal antibody that is conjugated with different radioisotopes for the treatment of advanced solid tumors express… Read more
Monopar Therapeutics Inc (MNPR) - Total Assets
Latest total assets as of September 2025: $144.20 Million USD
Based on the latest financial reports, Monopar Therapeutics Inc (MNPR) holds total assets worth $144.20 Million USD as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Monopar Therapeutics Inc - Total Assets Trend (2015–2024)
This chart illustrates how Monopar Therapeutics Inc’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Monopar Therapeutics Inc - Asset Composition Analysis
Current Asset Composition (December 2024)
Monopar Therapeutics Inc's total assets of $144.20 Million consist of 100.0% current assets and 0.0% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 76.0% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2015–2024)
This chart illustrates how Monopar Therapeutics Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Monopar Therapeutics Inc's current assets represent 100.0% of total assets in 2024, an increase from 71.7% in 2015.
- Cash Position: Cash and equivalents constituted 76.0% of total assets in 2024, up from 70.9% in 2015.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2015.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
Monopar Therapeutics Inc Competitors by Total Assets
Key competitors of Monopar Therapeutics Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
MedPacto Inc
KQ:235980
|
Korea | ₩51.58 Billion |
|
2H0
F:2H0
|
Germany | €15.27 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
|
Hualan Biological EngineeringInc
SHE:002007
|
China | CN¥16.27 Billion |
Monopar Therapeutics Inc - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Monopar Therapeutics Inc generates 0.00x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Monopar Therapeutics Inc is currently not profitable relative to its asset base.
Monopar Therapeutics Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 56.10 | 5.41 | 14.28 |
| Quick Ratio | 56.10 | 5.41 | 14.28 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $141.52 Million | $ 4.95 Million | $ 15.62 Million |
Monopar Therapeutics Inc - Advanced Valuation Insights
This section examines the relationship between Monopar Therapeutics Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.61 |
| Latest Market Cap to Assets Ratio | 4.53 |
| Asset Growth Rate (YoY) | 720.8% |
| Total Assets | $60.29 Million |
| Market Capitalization | $273.04 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values Monopar Therapeutics Inc's assets at a significant premium ( 4.53x), suggesting investors see substantial growth potential or unique competitive advantages.
Rapid Asset Growth: Monopar Therapeutics Inc's assets grew by 720.8% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Monopar Therapeutics Inc (2015–2024)
The table below shows the annual total assets of Monopar Therapeutics Inc from 2015 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $60.29 Million | +720.83% |
| 2023-12-31 | $7.35 Million | -44.47% |
| 2022-12-31 | $13.23 Million | -35.55% |
| 2021-12-31 | $20.52 Million | +21.66% |
| 2020-12-31 | $16.87 Million | +26.34% |
| 2019-12-31 | $13.35 Million | +82.46% |
| 2018-12-31 | $7.32 Million | -26.31% |
| 2017-12-31 | $9.93 Million | +242.98% |
| 2016-12-31 | $2.90 Million | +2.39% |
| 2015-12-31 | $2.83 Million | -- |